We're building the future of AI and biology together.
SynBioBeta 2027, May 3-6, San Jose.
George
Church
Harvard Medical School
Professor
Alex
Rives
Chan Zuckerberg Biohub
Head of Science
Karen
Akinsanya
Schrodinger
President, R&D – Therapeutics
Christopher
Arendt
Takeda
Chief Scientific Officer & Head of Research
Stef
van Grieken
Cradle
CEO
Michael
Koeris
DARPA
Director, BTO
Jennifer
Dionne
Pumpkinseed
CEO
Daniyal
Hussain
GSK
Executive Director of the Technology Business Development
Jacob
Glanville
Centivax
CEO
Cynthia
Hong
Novartis
Director, Search & Evaluation, Discovery Sciences & AI/Digital
Sarah Lynn
Tao
CSL Behring
CSL, S&E, Ig Therapeutic Area and Tech Lead
Ziwei
Liang
Pfizer
Innovation Fellow & Director
Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Joe
Hedley
NunaBio
Chief Executive Officer
Reagan
Jarvis
Anocca AB
Meet the Sponsors & Exhibitors
Why People Keep Coming Back
”
SynBioBeta is a who’s who of AI and biology. This is where the future is being built, so don't miss it.
Eric Schmidt
Former CEO
”
Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal.
Surge Biswas
Founder
”
I met Algen at SynBioBeta and later invested in the company. It's exactly the kind of connection that makes the community so valuable.
Bill Tai
Co-founder
”
For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta.
Celestine Schnugg
Founder
AI-powered therapeutics, precision medicine, and longevity. The founders, the pharma leaders, and the investors.
Synthesis, editing, multi-omics, and automation — the stack from base pair to bioreactor. The toolmakers, the platform builders, and the labs that run on them.
Foods, materials, chemicals, and ingredients made by biology — and priced to win. The founders, the manufacturers, and the buyers scaling them.
Where bio capital actually moves — deals, valuations, and non-dilutive funding. The VCs, the philanthropists, and the founders raising.
Foundation models, virtual cells, AI-designed molecules, and the companies putting them to work.
Synthesis screening, countermeasure capacity, and governance racing the tools. The scientists, the agencies, and the policymakers holding the line.
Early Bird Ends Midnight Wednesday, September 30. Lock In Your Rate Now.
All passes are fully refundable.
Students: Join our Next-Generation Leaders Program
Secure Your Spot in the Exhibit Hall
